Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

Exclusion Criteria

• •Obesity of known endocrine or genetic origin (eg, hypothyroidism, Cushing's syndrome or diagnosed polycystic ovarian syndrome) meeting one of the following conditions:
• •* Menstrual irregularity due to oligo- or anovulation
• •* Evidence of hyperandrogenism, whether clinical (hirsutism, acne, or male pattern balding) or biochemical (high serum androgen concentrations)
• •* Exclusion of other causes of hyperandrogenism and menstrual irregularity, such as congenital adrenal hyperplasia, androgen-secreting tumors, and hyperprolactinemia\]
• •History of malignancy within the previous 5 years with the exception of non-melanoma skin cancer or surgically cured cervical cancer
• •Human immunodeficiency virus (HIV) identified by history or previous HIV test
• •Any serious medical condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study including any clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs
• •Known history or evidence of a psychiatric disorder that in the opinion of the investigator would preclude the subject from participating in the trial. Stable or controlled anxiety or depression are permitted. Treatment with an antidepressant or anxiolytic drug is permitted if in accordance with Appendix 4. Subjects with a score of 11 or higher on the depression portion of the Hospital Anxiety and Depression Scale are excluded.
• •Subjects with pancreatitis or chronic pancreatic inflammation
• •History of Type 1 or Type 2 diabetes mellitus as defined by HbA1c \> 6.5% or blood glucose values of \> 126 mg/dl or treated Type 2 diabetes mellitus
• •Any weight gain during the single-blind lead-in period (Visit 1 and Visit 3)
• •History of surgical or device (eg, gastric bypass) intervention for obesity surgery, stomach banding surgery, or any other surgical procedure(s) that attempt to promote/aid weight loss. Note: Liposuction will be allowed if done more than 90 days prior to screening
• •History of alcoholism or drug addiction/substance abuse within 1 year of Visit 1. Note: No alcohol consumption is permitted within 48 hours prior to blood collections for analysis of lipid profiles.
• •Abnormal thyroid stimulating hormone level at screening
• •Subjects with hypothyroidism
• •Subjects with genetic hematologic disease or trait with or without manifestation of disease.
• •Use of chronic medications/products within 90 days prior to Visit 1 or during the study that are known to cause weight gain. Investigators will discuss with the Sponsor's Medical Monitor any concomitant medications about which they are uncertain.
• •Use of systemic corticosteroids or Depo Provera®
• •History of fenfluramine or dexfenfluramine (Fen-Phen) administration (except with a prior documented echocardiogram showing no valvular abnormalities.)
• •History of participation in any weight loss program within 90 days prior to Visit 1
• •Participation in any weight loss medication/product study in which receipt of weight loss medication/product occurred within 90 days prior to Visit 1
• •Use of any prescription or nonprescription over the counter medication/product or herbal/phytotherapeutic/plant-derived medications/products for weight loss, appetite suppression, weight control or treat obesity (includes investigational products) within 90 days prior to Visit 1 or during the study
• •Subjects with cholestasis or chronic malabsorption
• •Donation of blood or blood products 90 days prior to Visit 1 or during the study
• •Exposure to an investigative medication within the past 30 days or 5 half-lives, whichever is longer or concurrent participation in any clinical trial
• •Previous velneperit (S-2367) or other neuropeptide Y (NPY) Y5 agonist or antagonist use
• •Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study
• •Positive Hepatitis B or C serology